The unusual suspects - Innate lymphoid cells as novel therapeutic targets in IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 5, 2015, Pages 271-283

  Goldberg, Rimma ^a   Prescott, Natalie ^a   Lord, Graham M ^a   MacDonald, Thomas T ^b   Powell, Nick ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMG 139; ANRUKINZUMAB; APILIMOD; BI 655066; BRIAKINUMAB; BRODALUMAB; CANAKINUMAB; CYCLOSPORIN A; CYTOKINE; ETROLIZUMAB; FONTOLIZUMAB; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6 ANTIBODY; PF 04236921; PIMOZIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; TRALOKINUMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINE; CELL SUBPOPULATION; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; ENTERITIS; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; LYMPHOID CELL; MUCOSA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; B LYMPHOCYTE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INNATE IMMUNITY; INTESTINE; LYMPHOCYTE;

B-LYMPHOCYTE SUBSETS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINES; LYMPHOCYTES;

EID: 84929663292     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.52     Document Type: Review

References (127)

1. Parronchi, P. et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150, 823-832 (1997).
2. Breese, E., Braegger, C. P., Corrigan, C. J., Walker-Smith, J. A. & MacDonald, T. T. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78, 127-131 (1993).
3. Rovedatti, L. et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut 58, 1629-1636 (2009).
4. Fuss, I. J. et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996).
5. Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550-564 (2005).
6. Biancheri, P. et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur. J. Immunol. 44, 370-385 (2014).
7. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35-41 (2009).
8. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725 (2009).
9. Spits, H. & Cupedo, T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Ann. Rev. Immunol. 30, 647-675 (2012).
10. Constantinides, M. G., McDonald, B. D., Verhoef, P. A. & Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397-401 (2014).
11. Klose, C. S. et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157, 340-356 (2014).
12. Spits, H. et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013).
13. Szabo, S. J. et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669 (2000).
14. Fallon, P. G. et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203, 1105-1116 (2006).
15. + cells that provide innate mucosal immune defense. Immunity 29, 958-970 (2008).
16. -- lymphoid cells. EMBO J. 30, 2934-2947 (2011).
17. Gladiator, A., Wangler N., Trautwein-Weidner, K. & Leibund Gut-Landmann, S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J. Immunol. 190, 521-525 (2013).
18. + lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122-134 (2011).
19. Diefenbach, A., Colonna, M. & Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity 41, 354-365 (2014).
20. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503-510 (2008).
21. Chinen, H. et al. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 133, 559-573 (2007).
22. + natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139, 882-892 (2010).
23. + cells. Nat. Immunol. 10, 83-91 (2009).
24. Hall, L. J. et al. Natural killer cells protect mice from DSS-induced colitis by regulating neutrophil function via the NKG2A receptor. Mucosal Immunol. 6, 1016-1026 (2013).
25. +) innate lymphocytes. Immunity 33, 736-751 (2010).
26. Bernink, J. H. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14, 221-229 (2013).
27. Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781 (2013).
28. Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133 (2011).
29. Hazenberg, M. D. & Spits, H. Human innate lymphoid cells. Blood 124, 700-709 (2014).
30. + innate lymphoid cells. Immunity 37, 674-684 (2012).
31. -/- (TRUC) mice. Proc. Natl Acad. Sci. USA 111, E2559-2566 (2014).
32. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371-1375 (2010).
33. Gökmen, K. R. et al. Genome wide regulatory analysis reveals that T-bet controls Th17 lineage differentiation through direct suppression of IRF4. J. Immunol. 191, 5925-5932 (2013).
34. Sawa, S. et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat. Immunol. 12, 320-326 (2011).
35. Conti, H. R. et al. Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections. J. Exp. Med. 211, 2075-2084 (2014).
36. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
37. Nussbaum, J. C. et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502, 245-248 (2013).
38. Neill, D. R. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370 (2010).
39. Garrett, W. S. et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 33-45 (2007).
40. Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208-219 (2009).
41. + mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J. Exp. Med. 211, 1571-1583 (2014).
42. Sanjabi, S., Zenewicz, L. A., Kamanaka, M. & Flavell, R. A. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr. Opin. Pharmacol. 9, 447-453 (2009).
43. Wolk, K. et al. IL-22 increases the innate immunity of tissues. Immunity 21, 241-254 (2004).
44. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282-289 (2008).
45. Baert, F. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138, 463-468 (2010).
46. Brakenhoff, L. K., van der Heijde, D. M., Hommes, D. W., Huizinga, T. W. & Fidder, H. H. The joint-gut axis in inflammatory bowel diseases. J. Crohns Colitis 4, 257-268 (2010).
47. De Vos, M., Mielants, H., Cuvelier, C., Elewaut, A. & Veys, E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 110, 1696-1703 (1996).
48. Di Meglio, P. et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE 6, e17160 (2011).
49. Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730-738 (2013).
50. De Lay, M. L. et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 60, 2633-2643 (2009).
51. Azuz-Lieberman, N. et al. The involvement of NK cells in ankylosing spondylitis. Int. Immunol. 17, 837-845 (2005).
52. Ciccia, F. et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 64, 1869-1878 (2012).
53. Bailey, J. R. et al. IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells? PLoS ONE 7, e52332 (2012).
54. Hashguchi, M. et al. Peyer's patch innate lymphoid cells regulate commensal bacteria expansion. Immuno. Lett. 165, 1-9 (2015).
55. Kamada, N. et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm. Bowel Dis. 16, 568-575 (2010).
56. + LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 33, 752-764 (2010).
57. von Burg, N. et al. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. Proc. Natl Acad. Sci. USA 111, 12835-12840 (2014).
58. Norton, N.C. & Mathew, P. A. NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front. Immunol. 6, 31 (2015).
59. + innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 38, 1223-1235 (2013).
60. Satoh-Takayama, N. et al. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J. Immunol. 183, 6579-6587 (2009).
61. Bain, C. C. et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15, 929-937 (2014).
62. Bain, C. C. & Mowat, A. M. Macrophages in intestinal homeostasis and inflammation. Immunol. Rev. 260, 102-117 (2014).
63. Bain, C. C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498-510 (2013).
64. Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118, 2269-2280 (2008).
65. Ogino, T. et al. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease. Gastroenterology 145, 1380-1391 (2013).
66. Mizuno, S. et al. Cross-talk between RORgammat+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease. Inflamm. Bowel Dis. 20, 1426-1434 (2014).
67. Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).
68. Hepworth, M. R. et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498, 113-117 (2013).
69. Sonnenberg, G. F., Fouser, L. A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383-390 (2011).
70. Goto, Y. et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 40, 594-607 (2014).
71. Withers, D. R. et al. Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissue. J. Immunol. 189, 2094-2098 (2012).
72. Magri, G. et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 15, 354-364 (2014).
73. Xie, M. H. et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275, 31335-31339 (2000).
74. Nagalakshmi, M L., Rascle, A., Zurawski, S., Menon, S. & de Waal Malefyt, R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int. Immunopharmacol. 4, 679-691 (2004).
75. Goto, Y. et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345, 1254009 (2014).
76. Pham, T. A. et al. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16, 504-516 (2014).
77. Sonnenberg, G. F. et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336, 1321-1325 (2012).
78. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485-498 (2009).
79. Qiu, J. et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39, 386-399 (2013).
80. + innate lymphoid cells. Front. Immunol. 3, 72 (2012).
81. Spencer, S. P. et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 343, 432-437 (2014).
82. Mielke, L. A. et al. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J. Exp. Med. 210, 1117-1124 (2013).
83. Papier, K. et al. Childhood malnutrition and parasitic helminth interactions. Clin. Infect. Dis. 59, 234-243 (2014).
84. Kiss, E. A. et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 334, 1561-1565 (2011).
85. Qiu, J. et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36, 92-104 (2012).
86. Kiss, E. A. & Diefenbach, A. Role of the aryl hydrocarbon receptor in controlling maintenance and functional programs of RORgammat(+) innate lymphoid cells and intraepithelial lymphocytes. Front. Immunol. 3, 124 (2012).
87. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
88. Hu, X. et al. Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am. J. Hum. Genet. 89, 496-506 (2011).
89. Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
90. Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
91. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
92. Momozawa, Y. et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat. Genet. 43, 43-47 (2011).
93. Rivas, M. A. et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat. Genet. 43, 1066-1073 (2011).
94. Biancheri, P., Powell, N., Monteleone, G., Lord, G. & MacDonald, T. T. The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol. 34, 564-571 (2013).
95. Kock, K. et al. Preclinical development of AMG 139, a human antibody specifically targetting IL-23. Br. J. Pharmacol. 172, 159-172 (2014).
96. Sutton, C. E., Mielke, L. A. & Mills, K. H. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 42, 2221-2231 (2012).
97. Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012).
98. Niederreiter, L., Adolph, T. E. & Kaser, A. Anti-IL-12/23 in Crohn's disease: bench and bedside. Curr. Drug Targets. 14, 1379-1384 (2013).
99. Satsangi, J. et al. Interleukin 1 in Crohn's disease. Clin. Exp. Immunol. 67, 594-605 (1987).
100. McAlindon, M. E., Hawkey, C. J. & Mahida, Y. R. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42, 214-219 (1998).
101. Reinecker, H. C. et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181 (1993).
102. Liu, Z. et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J. Immunol. 164, 3608-3615 (2000).
103. Monteleone, G., Fina, D., Caruso R. & Pallone, F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 22, 361-364 (2006).
104. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996 (2004).
105. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
106. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01345318?term=PF04236921&rank=5 (2015).
107. + Th17 cells. J. Exp. Med. 209, 1595-1609 (2012).
108. Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the update of the 2013 EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheumat. Dis. 73, 516-528 (2014).
109. Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396-2406 (2012).
110. Ilowite, N. T. et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 66, 2570-2579 (2014).
111. Chen, H. et al. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem. 82, 195-203 (2014).
112. Bendell, J. C. et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. 74, 125-130 (2014).
113. Targan, S. R. et al. A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe crohn's disease [abstract Mo2083]. Gastroenterology 143, e26 (2012).
114. Reinisch, W. et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233-242 (2010).
115. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
116. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
117. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01853033?term=ABT-122&rank=22014 (2014).
118. Munneke, J. M. et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124, 812-821 (2014).
119. Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
120. Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699-710 (2013).
121. Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369, 711-721 (2013).
122. Rutgeerts, P. J. et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 62, 1122-1130 (2013).
123. Watanabe, M. et al. AJM300, an oral α4 integrin antagonist, for active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled phase 2a study [abstract 370]. Gastroenterology 146, S82 (2014).
124. Vermeire, S. et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 60, 1068-1075 (2011).
125. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01316601 (2011).
126. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01284062?term=anrukinzumab&rank=1 (2014).
127. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01482884?term=tralokinumab&rank=2 (2015).